Artrya Ltd (AYA)

Currency in AUD
4.11
+0.06(+1.48%)
Closed·

AYA Earnings

Latest Release
Feb 25, 2026
EPS / Forecast
-0.09 / --
Revenue / Forecast
14K / --
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2025/12-0.090/--14.00K/------Free Sign Up
2025/06-0.090/--15.00K/------Free Sign Up
2024/12-0.090/--13.00K/------Free Sign Up
2022/12-0.080/----/------Free Sign Up
2022/06-0.190/----/------Free Sign Up
2021/12-0.080/----/------Free Sign Up

All numbers in AUD

Artrya Ltd Earnings Call Summary for Q2/2026

  • Artrya Ltd reported Q2 2026 customer receipts of $60,000, raised AUD 80 million, and maintained AUD 76.5 million in cash reserves despite a 1.27% stock price decline to $3.53.
  • The company successfully converted three U.S. foundation partners into full commercial customers and established an on-ground customer success team to strengthen its American market presence.
  • Artrya launched the Salix Coronary Plaque module and is targeting FDA clearance for its Flow module by June 2026, aiming to capture a share of 400,000 annual CCTA scans in the U.S.
  • Management expects to fully integrate U.S. customers and increase foundation customer engagement by FY27, with SAPPHIRE partners inclusion anticipated by FY28.
  • Operating outflows decreased to $5.4 million from $6.1 million in the previous quarter, reflecting improved operational efficiency as the company expands.
Last Updated: 2026-02-01, 07:48 p/m
Read Full Transcript

FAQ

What Is Artrya's Earnings Per Share (TTM)?

The Artrya EPS (TTM) is -0.17.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.